As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...
The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback